SERNOVA WKN: A0LBCR ISIN: CA81732W1041 Kürzel: SVA Forum: Aktien Thema: Hauptdiskussion

we are just as frustrated with the share price as investors are. Addressing your email below, cash plus cash equivalents at the end of Q2/24 was $8.5m so more than you are citing in your email below however you are correct the company will need additional cash. Management and the Board are working diligently to put a plan together as soon as there is something that can be shared publicly we will do so. With respect to news flow we did give investors a clinical update 2 weeks ago with another patient now insulin independent and will continue to bring updates as they become available. With respect to potential partnerships, Modi is working with several outside pharma companies on potential collaborations etc., however this is also highly confidential and cannot be disclosed until a transaction is consummated or we risk losing whatever work has been done. Depending on who the partner is and how the agreement is structured there could very well be cash as part of a transaction. The next pending regulatory approval would be for the thyroid program which we would like to get into the clinic early in 2025, you should expect that the associated filings are being worked on and we expect to have the IND filed by end of year. I hope this helps, Christopher Barnes Vice President Investor Relations Sernova

Buschis Zweitaccount?

Was sagen eigentlich der Aktien-Guru Karsten Busche und seine Lemminge zu der Kursentwicklung? "Aggressiv kaufen"?

Die Messe ist gelesen

Habe keine Angst,Jaxt.Bald musst du es auch einsehen: hier kommt nichts mehr, außer die nicht versprochen Kapitalerhöhung 🇨🇦

Auf geht’s Richtung 10 Cent. Mal gucken ob es sernova noch dieses Jahr schafft. Was für eine Kanadabude.